Please assess the completion status of the following clinical trial:

Trial Title: Ibodutant for Relief of Irritable Bowel Syndrome With Diarrhoea (IBS-D)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~At start of the run-in period:~* Male or female patients aged 18 - 70 years with a clinical diagnosis of IBS-D according to the Rome III criteria:~* Recurrent abdominal pain/discomfort for at least 3 days per month in the last 3 months associated with at least 2 of the following characteristics:~  1. improvement with defecation;~ 2. onset associated with a change in the frequency of stool;~ 3. onset associated with a change in form (appearance) of stool.~* Symptom-onset at least 6 months prior to diagnosis.~* Loose/watery stools at least 25% of the time in the last 3 months AND hard/lumpy stools less than 25% of the time in the last 3 months.~* More than 3 bowel movements per day at least 25% of the time in the last 3 months.~* For patients older than 50 years OR patients with positive family history of colorectal cancer: Normal results from colonoscopy or flexible sigmoidoscopy.~* Mentally competent, able to give written informed consent.~* For women of childbearing potential: Use of a highly effective contraceptive method throughout the entire study period and up to 30 days post-treatment.~* Normal physical examination or without clinically relevant abnormalities.~At randomisation:~-Confirmation of IBS-D severity in terms of bowel movement frequency and abdominal pain intensity along the 2-week run-in period.~Exclusion criteria:~* Organic abnormalities of the gastrointestinal tract, including history of colonic or major abdominal surgery.~* History of gluten enteropathy.~* Lactose intolerance as assessed by response to diet.~* History of positive tests for ova or parasites, or occult blood in the stool.~* Previous diagnosis of diabetes mellitus (either type 1 or 2).~* Unstable medical condition.~* Major psychiatric, neurological, or cardiovascular disorders, or uncontrolled metabolic disease.~* Relevant changes in dietary habits, lifestyle, or exercise regimen in the previous 2 months.~* Use of concurrent medication with drugs known to interfere with gastro-intestinal motility or sensitivity.~* Pregnancy or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Ibodutant low dose (Type: EXPERIMENTAL): Oral tablet, to be given once daily in fasting conditions.
- Ibodutant intermediate dose (Type: EXPERIMENTAL): Oral tablet, to be given once daily in fasting conditions.
- Ibodutant high dose (Type: EXPERIMENTAL): Oral tablet, to be given once daily in fasting conditions.
- Placebo (Type: PLACEBO_COMPARATOR): Oral tablet, to be given once daily in fasting conditions.

Based on this trial design, predict the completion outcome and termination type (if applicable).